Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simvastatin in Graves' Ophthalmopathy (GO-S)
NCT03131726Phase 3Recruiting
- Sponsor
- Lund University
- Start
- Jan 2018
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of simvastatin in Graves' ophthalmopathy (TED) (2 arms), sponsored by Lund University. Primary endpoints: Clinical Activity Score at 6 months and Progression to severe Graves' ophthalmopathy at 6 months. Started Jan 2018; status: recruiting.
02
Drugs
simvastatin
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on NCT03131726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03131726.